title: Treatment of alopecia areata in the DEBR model using Cyclosporin A lipid vesicles.
abstract: Alopecia areata (AA) is a chronic cutaneous disease with a suspected autoimmune origin. We evaluated the efficacy of 0.5% Cyclosporin A (CyA) in a topically applied liposomal formulation as a potential treatment for AA using the Dundee Experimental Bald Rat (DEBR) model. The vehicle consisted of liposomes (75% phosphatidylcholine, 5% lysophosphatidylcholine, 5% sterol, natural oils) of 10% wt. in ethanol with and without 2% wt. terpenes (d-limonene: citral: cineole, 10:45:45) as a penetration enhancer (PE). Fifteen DEBR were allocated to 3 groups of 5. Groups I, II and III received CyA vesicles with PE, CyA vesicles without PE, and CyA in ethanol respectively. All rats were treated twice a day for 6 weeks within a 4 cm2 area on one bald flank with CyA while the contralateral flank received an equivalent control formulation. Rats in group I exhibited visible hair regrowth on the drug treated site after one week of drug application. Group II rats had visible hair regrowth by the end of the second week. The hair growth was progressive and reached a maximum density at the site of application after six weeks in both groups. Histological examination revealed a reduced inflammatory infiltrate and improved hair follicle morphology within the drug treated area as compared to the contralateral vehicle treated skin. Group III rats showed neither visible signs of hair growth nor reduction of hair follicle inflammation. The results of this proof of concept preliminary study suggest that CyA vesicle formulations with and without PE have promising potential as a topical treatment for AA in humans.
authors.affiliation: Institute for Pharmaceutical Technology and Biopharmacy, Department of Pharmaceutical Sciences, Bouve College of Health Sciences, 312 Mugar Building, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. ddverma@yahoo.com
authors.forename: D D
authors.initials: DD
authors.lastname: Verma
authors.forename: S
authors.initials: S
authors.lastname: Verma
authors.forename: K J
authors.initials: KJ
authors.lastname: McElwee
authors.forename: P
authors.initials: P
authors.lastname: Freyschmidt-Paul
authors.forename: R
authors.initials: R
authors.lastname: Hoffman
authors.forename: A
authors.initials: A
authors.lastname: Fahr
mesh_terms: D000279:Administration, Cutaneous; D000506:Alopecia Areata / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008081:Liposomes; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D007166:Immunosuppressive Agents; D008081:Liposomes; D016572:Cyclosporine